Earnings History Data for Nektar Therapeutics (NKTR) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain. In the area of pain, Nektar has a worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation. The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid. Also in the area of pain, NKTR-181, the company's wholly-owned novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies. Nektar Therapeutics is headquartered in San Francisco, California.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
08-05-2025	AH		NKTR	Nektar Therapeutics	119.48	-0.22	-0.17	-0.18	Nektar Therapeutics Non-GAAP EPS of -$0.22 misses by $0.03, revenue of $10.46M misses by $4.9M [5/8/2025 4:24 PM]	0.5855	-0.03 (-5.40%)	0.60	-0.02 (-3.05%)	0.43 - 1.93	1,723,187	2,080,000	11,040
Nektar Therapeutics Non-GAAP EPS of -$0.22 misses by $0.03, revenue of $10.46M misses by $4.9M [5/8/2025 4:24 PM] Nektar therapeutics outlines REZOLVE-AD phase 2b data and financial position for Q2 2025 [5/8/2025 10:09 PM]
12-03-2025	AH		NKTR	Nektar Therapeutics	151.00	-0.15	-0.13	0.00	Nektar Therapeutics Non-GAAP EPS of $0.15 beats by $0.35, revenue of $29.17M misses by $7.49M [3/12/2025 4:18 PM]	0.8201	0.0 (0.01%)	0.85	0.03 (3.66%)	0.65 - 1.93	980,436	1,320,000	9,563
Nektar Therapeutics Non-GAAP EPS of $0.15 beats by $0.35, revenue of $29.17M misses by $7.49M [3/12/2025 4:18 PM] Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results [2025-03-12 04:15PM] Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... [2025-03-13 03:09AM] Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say [Mar-12-25 08:30PM] Nektar Therapeutics (NKTR) Q4 Earnings Beat Estimates [Mar-12-25 07:00PM] Nektar: Q4 Earnings Snapshot [Mar-12-25 06:12PM]
07-11-2024	AH		NKTR	Nektar Therapeutics	257.71	-0.18	-0.22	-0.19	Nektar Therapeutics GAAP EPS of -$0.18 beats by $0.03, revenue of $24.12M beats by $5.84M [11/7/2024 4:23 PM]	1.40	0.03 (2.18%)	1.38	0.01 (0.73%)	0.41 - 1.93	1,439,418	2,030,000	15,119
Nektar releases promising phase 2 results for NKTR-255 in lymphopenia [11/7/2024 1:30 PM] Nektar Therapeutics GAAP EPS of -$0.18 beats by $0.03, revenue of $24.12M beats by $5.84M [11/7/2024 4:23 PM] Nektar Therapeutics to Participate in Upcoming Investor Conferences [Nov-06-24 06:00PM] Nektar Therapeutics Reports Third Quarter 2024 Financial Results [2024-11-07 04:15PM] Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting [2024-11-07 10:15AM]
08-08-2024	AH		NKTR	Nektar Therapeutics	214.84	-0.25	-0.21	-0.27	Nektar Therapeutics Non-GAAP EPS of -$0.19, revenue of $23.49M [8/8/2024 5:50 PM]	1.11	-0.09 (-7.85%)	1.19	-0.02 (-1.65%)	0.41 - 1.93	1,011,906	1,010,000	312
Nektar Therapeutics Non-GAAP EPS of -$0.19, revenue of $23.49M [8/8/2024 5:50 PM]
09-05-2024	AH		NKTR	Nektar Therapeutics	275.43	-0.18	-0.21	-0.25	Nektar Therapeutics GAAP EPS of -$0.19, revenue of $21.6M [5/9/2024 4:22 PM]	1.75	0.15 (9.38%)	1.62	0.02 (1.32%)	0.41 - 1.87	2,238,669	1,400,000	8,543
Nektar Therapeutics GAAP EPS of -$0.19, revenue of $21.6M [5/9/2024 4:22 PM]
04-03-2024	AH		NKTR	Nektar Therapeutics	135.00	-0.22	-0.20	0.00	Nektar Therapeutics GAAP EPS of -$0.22 misses by $0.01, revenue of $23.89M beats by $2.52M [3/4/2024 4:17 PM]	0.8803	-0.02 (-2.19%)	0.89	-0.01 (-1.12%)	0.41 - 1.59	5,143,570	3,560,000	80,498
Nektar Therapeutics enters into a $30M private placement financing agreement [3/4/2024 9:08 AM] Nektar Therapeutics GAAP EPS of -$0.22 misses by $0.01, revenue of $23.89M beats by $2.52M [3/4/2024 4:17 PM]
07-11-2023	AH		NKTR	Nektar Therapeutics	104.57	-0.19	-0.18	-0.24	Nektar Therapeutics Non-GAAP EPS of -$0.19 misses by $0.03, revenue of $24.1M beats by $2.79M [11/7/2023 4:19 PM]	0.5059	-0.04 (-7.68%)	0.52	-0.03 (-6.02%)	0.44 - 4.36	1,146,183	2,200,000	14,080
Nektar Therapeutics Non-GAAP EPS of -$0.19 misses by $0.03, revenue of $24.1M beats by $2.79M [11/7/2023 4:19 PM]
08-08-2023	AH		NKTR	Nektar Therapeutics	100.79	-0.27	-0.30	-0.85	Nektar Therapeutics GAAP EPS of -$0.27 beats by $0.01, revenue of $20.5M misses by $1.33M [8/8/2023 5:00 PM]	0.9090	-0.09 (-9.10%)	0.94	-0.06 (-6.22%)	0.51 - 5.18	15,886,598	22,150,000	568,417
Nektar Therapeutics GAAP EPS of -$0.27 beats by $0.01, revenue of $20.5M misses by $1.33M [8/8/2023 5:00 PM]
09-05-2023	AH	4:15 PM ET (May 9)	NKTR	Nektar Therapeutics	154.91	-0.25	-0.25	-0.49		0.7449	-0.02 (-3.10%)	0.79	0.02 (2.12%)	0.60 - 5.18	3,737,293	2,060,000	4,237

03-11-2022	AH	4:15 PM ET (Nov 3)	NKTR	Nektar Therapeutics	714.01	-0.24	-0.47	-0.70	Nektar Therapeutics GAAP EPS of -$0.31 beats by $0.15, revenue of $23.63M beats by $1.02M [11/3/2022 4:22 PM]	3.77	0.21 (5.76%)	3.56	0.0 (0.00%)	2.96 - 17.79	937,089	1,090,000	40,314
Nektar Therapeutics GAAP EPS of -$0.31 beats by $0.15, revenue of $23.63M beats by $1.02M [11/3/2022 4:22 PM]
04-08-2022	AH	4:15 PM ET (Aug 4)	NKTR	Nektar Therapeutics	685.49	-0.85	-1.01	-0.69	Nektar Therapeutics GAAP EPS of -$0.85 beats by $0.15, revenue of $21.6M misses by $1.15M [8/4/2022 4:33 PM]	4.88	0.46 (10.41%)	4.88	0.0 (0.00%)	3.02 - 19.37	2,381,430	2,000,000	19,121
Nektar Therapeutics GAAP EPS of -$0.85 beats by $0.15, revenue of $21.6M misses by $1.15M [8/4/2022 4:33 PM] Nektar Therapeutics Reports Second Quarter 2022 Financial Results [Aug-04-22 04:15PM]
28-02-2022	AH	4:15 PM ET (Feb 28)	NKTR	Nektar Therapeutics	1,880	-0.79	-0.81	-0.65		10.95	0.71 (6.93%)	10.55	0.31 (3.03%)	9.31 - 24.50	1,816,348	1,720,000	3,912
Nektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results [Feb-28-22 04:15PM] Nektar Therapeutics (NKTR) Reports Q4 Loss, Lags Revenue Estimates [Feb-28-22 05:35PM] Billionaire Stanley Druckenmiller Just Dumped These 10 Stocks [Mar-01-22 10:43AM] Nektar (NKTR) Q4 Earnings Top, Three Bempeg Filings Due in 2022 [Mar-01-22 09:55AM]
04-11-2021	AH	4:15 PM ET (Nov 4)	NKTR	Nektar Therapeutics	2,980	-0.70	-0.80	-0.61	Nektar Therapeutics EPS beats by $0.10, misses on revenue [11/4/2021 4:26 PM]	13.44	-3.21 (-19.31%)	14.50	-2.15 (-12.91%)	12.35 - 26.75	5,095,591	1,020,000	73,315
Nektar Therapeutics EPS beats by $0.10, misses on revenue [11/4/2021 4:26 PM] Nektar Therapeutics shares slide 22% after Q3 topline miss, cash position update [11/5/2021 10:07 AM] Nektar Therapeutics Reports Third Quarter 2021 Financial Results [Nov-04-21 04:15PM] Nektar Therapeutics (NKTR) Reports Q3 Loss, Misses Revenue Estimates [Nov-04-21 05:35PM] Nektar Therapeutics (NKTR) Q3 2021 Earnings Call Transcript [Nov-04-21 10:32PM] Nektar (NKTR) Q3 Earnings Top, Pipeline Remains On Track [Nov-05-21 11:00AM] Why Nektar Therapeutics Stock Plunged Today [Nov-05-21 04:11PM]
05-08-2021	AH	4:15 PM ET (Aug 5)	NKTR	Nektar Therapeutics	2,880	-0.69	-0.72	-0.45	Nektar Therapeutics EPS beats by $0.04, beats on revenue [8/5/2021 4:29 PM]	15.74	-0.13 (-0.80%)	15.87	0.0 (0.00%)	15.37 - 26.75	708,008	640,000	14,966
Nektar Therapeutics Reports Second Quarter 2021 Financial Results [Aug-05-21 04:15PM] Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates [Aug-05-21 05:45PM] Nektar Therapeutics (NKTR) Q2 2021 Earnings Call Transcript [Aug-05-21 09:31PM] Nektar (NKTR) Q2 Earnings and Revenues Top, Pipeline On Track [Aug-06-21 12:31PM]
06-05-2021	AH	4:15 PM ET (May 6)	NKTR	Nektar Therapeutics	3,430	-0.68	-0.74	-0.53	Nektar Therapeutics EPS beats by $0.07, misses on revenue [5/6/2021 4:16 PM]	20.10	1.58 (8.53%)	20.10	0.0 (0.00%)	15.39 - 26.75	2,859,113	800,000	43,920
Nektar Therapeutics EPS beats by $0.07, misses on revenue [5/6/2021 4:16 PM] Nektar Therapeutics shares rise on narrower Q1 loss [5/7/2021 11:43 AM] Nektar Therapeutics Reports First Quarter 2021 Financial Results [May-06-21 04:15PM] Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates [May-06-21 05:45PM] Nektar Therapeutics (NKTR) Q1 2021 Earnings Call Transcript [May-07-21 03:30AM]
25-02-2021	AH	4:15 PM ET (Feb 25)	NKTR	Nektar Therapeutics	4,040	-0.65	-0.72	-0.64	Nektar Therapeutics EPS beats by $0.03, misses on revenue [2/25/2021 4:22 PM]	22.80	0.36 (1.60%)	22.14	-0.30 (-1.34%)	13.63 - 26.75	1,228,767	1,596,589	491
Nektar Therapeutics EPS beats by $0.03, misses on revenue [2/25/2021 4:22 PM] Nektar (NKTR) Q4 Earnings and Revenues Top, Pipeline On Track [Feb-26-21 09:09AM] Need To Know: The Consensus Just Cut Its Nektar Therapeutics (NASDAQ:NKTR) Estimates For 2021 [Feb-26-21 07:20AM] Nektar Therapeutics (NKTR) Q4 2020 Earnings Call Transcript [Feb-26-21 01:01AM] Nektar Therapeutics: Q4 Earnings Insights [Feb-25-21 05:10PM] Nektar Therapeutics to Host Earnings Call [Feb-25-21 03:15PM]
05-11-2020	AH	4:15 PM ET (Nov 5)	NKTR	Nektar Therapeutics	2,820	-0.61	-0.80	-0.56	Nektar Therapeutics EPS beats by $0.16, beats on revenue [11/5/2020 4:25 PM]	17.41	0.52 (3.08%)	17.00	0.11 (0.65%)	13.63 - 28.60	1,444,410	1,241,188	1,166

06-08-2020	AH	4:15 PM ET (Aug 6)	NKTR	Nektar Therapeutics	3,930	-0.45	-0.69	-0.63	Nektar Therapeutics EPS beats by $0.23, beats on revenue [8/6/2020 4:19 PM]	22.50	0.99 (4.60%)	22.59	1.08 (5.02%)	13.63 - 29.99	585,187	801,153	1,557